What top creators are saying about Twist Bioscience Corp(TWST)

Appeared in a performance screen as having risen about 300%; no fundamental analysis or investment recommendation was provided.

Cited as a year-to-date leader with an approximate 300% gain; the discussion cautioned that gains alone do not establish investment merit.

Reported up about 7%; no company-specific analysis or recommendation was provided.

The host said he was long Twist Bioscience but provided no specific investment thesis or price target.

Could benefit if AI increases demand for biological materials used to test and develop molecule designs, but the thesis was tentative and no financial impact was established.

The speaker described years of steady growth and called the stock expensive at higher levels, but said it might not be the best short candidate and emphasized the difficulty and risk of shorting.

The speaker said the company had grown steadily for years and was difficult to short, despite considering the stock expensive at earlier levels. No buy recommendation was given.

The host expects a short-term decline and warned that the sharply higher longer-term chart could face a substantial correction.

Described as a real, rapidly growing business that has compounded over time. The stock was called very expensive, but the speaker cautioned against shorting a fast-growing company solely on valuation and did not want to time when growth might slow.

The speaker planned to examine the company later but expressed no investment view.

The speaker acknowledged revenue growth and possible strategic value, but considered the valuation excessive given low margins, ongoing losses, and uncertainty about sustained growth and profitability.

The speaker grouped Twist with companies he considered overvalued, without giving a specific trade recommendation.

A speaker had shorted the stock after a sharp drop and saw potential for further downside, while cautioning that the decline could be only a pullback after a historic run and might not continue.

The speaker viewed the valuation as excessive and highlighted low gross margins and continuing losses, but was reluctant to short because of the company's history of strong growth.

The host said he was short and saw substantial downside, while warning that the stock could continue rising and that a brief decline did not end the rally.

Grouped with stocks the host considered overvalued, but no company-specific evidence or valuation analysis was provided.

Favored as a picks-and-shovels beneficiary of AI drug discovery; AI-enabled orders are cited as growing at triple-digit rates in FY26 and FY27.

The speaker noted that the stock had risen sharply but gave no investment thesis.

A speaker thought the stock might continue rising but also wanted to short it because it looked expensive, reflecting tension between momentum and valuation concerns.

The speaker expressed skepticism about the company and said hedge-fund de-grossing was contributing to the stock's decline, rather than a change in fundamentals.

Shkreli was bearish, arguing that investors in the company were mistaken. He attributed some of the stock's decline to hedge-fund deleveraging and forced selling rather than new company-specific information.

Twist was described as a stock that was dropping, with no clear position, valuation thesis, or recommendation.

Considered a high-risk contrarian short candidate, though caution is advised against fading its strong upward momentum without technical breakdown confirmation.

Leading indicator of renewed momentum in the bioinformatics and genomics sector.

Poised to benefit from tech sector capital rotation and M&A interest due to valuable proprietary bioinformatics and biological data assets.

A leader in synthetic DNA that could benefit from regulatory moats created by mandatory screening protocols for DNA/RNA synthesis.

Involved in DNA synthesis screening discussions; faces potential new regulatory mandates for record-keeping.

Positioned as a key infrastructure provider supporting the broader genetic engineering and synthetic biology sector's shift to productionization.